Home/Pipeline/Balomenib

Balomenib

Type 2 Diabetes

Phase 1bActive

Key Facts

Indication

Type 2 Diabetes

Phase

Phase 1b

Status

Active

Company

Clywedog Therapeutics

About Clywedog Therapeutics

Clywedog Therapeutics is a UK-based biotech founded in 2020, pivoting from an initial focus on hematological cancers to metabolic diseases. Its core strategy involves developing novel small molecules, with a lead program (balomenib) now in a Phase 1b study for Type 2 Diabetes. The company is positioned for growth following a planned merger with Barinthus Biotherapeutics, aiming to create a combined entity targeting metabolic and autoimmune diseases.

View full company profile

Therapeutic Areas

Metabolic Disease Diabetes

Other Type 2 Diabetes Drugs

Drug	Company	Phase	Status
Diabetes Management Gel	Gelteq Limited	Formulation Development	Active
Tolimidone	Biodexa Pharmaceuticals	Phase 2	Acquired Asset
Generic Semaglutide Injection (Obeda)	Dr. Reddy's Laboratories	Approved	Launched in India
BioChaperone® Lispro	Adocia	Phase 3	Active
BioChaperone® Combo (Insulin Glargine / Lixisenatide)	Adocia	Phase 2	Active
AJN003 (LuCI™)	AltrixBio	Pre-clinical	Advancing to Phase 1 (planned 2026)
Hepatic Denervation for Type 2 Diabetes	Metavention	Feasibility	Active
MVD-1 (SANA)	Eolo Pharma	Discovery	Active
V-Go	MannKind	Approved	Active
Type 2 Diabetes Management	iWel	Development	Active
Band-assisted Duodenal Mucosal Resurfacing (DMR)	Endolastic	Pre-clinical	Active
REMD-477 (Volagidemab)	REMD Biotherapeutics	Phase 2 (completed)	Active